US 12,240,911 B2
Bispecific antibodies specific for OX40
Maria Amann, Schlieren (CH); Peter Bruenker, Schlieren (CH); Christina Claus, Schlieren (CH); Claudia Ferrara Koller, Schlieren (CH); Sandra Grau-Richards, Schlieren (CH); Ralf Hosse, Schlieren (CH); Christian Klein, Schlieren (CH); Viktor Levitski, Schlieren (CH); and Pablo Umana, Schlieren (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Nov. 14, 2019, as Appl. No. 16/684,258.
Application 16/684,258 is a continuation of application No. 15/280,379, filed on Sep. 29, 2016, granted, now 10,526,413.
Claims priority of application No. 15188095 (EP), filed on Oct. 2, 2015; and application No. 16170363 (EP), filed on May 19, 2016.
Prior Publication US 2020/0071411 A1, Mar. 5, 2020
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [C07K 16/30 (2013.01); C07K 16/3053 (2013.01); C07K 16/40 (2013.01); C12Y 304/14005 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. An antibody or antibody fragment thereof that specifically binds to OX40, wherein said antibody or fragment thereof comprises:
(a) a heavy chain variable domain (VH) comprising:
(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:2;
(ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:4;
(iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:6; and
(b) a light chain variable domain (VL) comprising:
(i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13;
(ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
(iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:19.